Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ether SCHEMBL9004240 | 0.80 | ALDH1A1 (0.33) | — | |
| SCHEMBL12614110 | 0.78 | CHRM3 (0.31) | CHRM3 | |
| Alcohol SCHEMBL11829915 | 0.78 | ALDH1A1 (0.35) | — | |
| Ethyl Chloride SCHEMBL11238720 | 0.78 | — | — | |
| SCHEMBL18960 | 0.76 | — | — | |
| SCHEMBL656963 | 0.76 | CHRNA7 (0.33) | — | |
| Bromomethane SCHEMBL11249828 | 0.74 | — | — | |
| Iodomethane SCHEMBL11255462 | 0.74 | — | — | |
| Adamantane SCHEMBL151782 | 0.74 | EPHX2 (0.34) | — | |
| Methyl Alcohol SCHEMBL3390479 | 0.74 | CHRM2 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023213740-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | PHILIP MORRIS PRODUCTS S.A. (CH) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023205249-A1 | NICOTINE AND NICOTINIC AGONIST COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF PANCREATITIS AND METHODS OF USING SAME | DUKE UNIVERSITY (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023279162-A1 | METHODS OF TREATMENT AND INHIBITION | UNIVERSITY OF CANBERRA (AU) | 2023-01-12 | — | — | WO | disclosed |
| EP-2308875-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives as .alpha.7 nAChR modulators | Abbott Laboratories (US) | 2011-04-13 | — | — | EP | disclosed |
| EP-2253631-A1 | Spyrocyclic quiniclidinic ether derivatives | Abbott Laboratories (US) | 2010-11-24 | — | — | EP | disclosed |
| US-7674794-B2 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES (US) | 2010-03-09 | — | — | US | disclosed |
| US-7655657-B2 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES (US) | 2010-02-02 | — | — | US | disclosed |
| US-20080064703-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBVIE INC. | 2008-03-13 | — | — | US | disclosed |
| EP-1896469-A2 | FUSED BICYCLOHETEROCYCLE SUBSTITUTED QUINUCLIDINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2008-03-12 | — | — | EP | disclosed |
| US-7309699-B2 | 3-Quinuclidinyl amino-substituted biaryl derivatives | ABBOTT LABORATORIES (US) | 2007-12-18 | — | — | US | disclosed |
| WO-2005066167-A2 | 3-QUINUCLIDINYL HETEROATOM BRIDGED BIARYL DERIVATIVES | ABBOTT LABORATORIES (US) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005066166-A2 | 3-QUINUCLIDINYL AMINO-SUBSTITUTED BIARYL DERIVATIVES | ABBOTT LABORATORIES (US) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005066168-A1 | SPIROCYCLIC QUINUCLIDINIC ETHER DERIVATIVES | ABBOTT LABORATORIES (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050137217-A1 | Spirocyclic quinuclidinic ether derivatives | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
| US-20050137226-A1 | 3-Quinuclidinyl heteroatom bridged biaryl derivatives | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
| US-20050137203-A1 | 3-quinuclidinyl amino-substituted biaryl derivatives | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
| US-20050137398-A1 | 3-Quinuclidinyl heteroatom bridged biaryl derivatives | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
| US-20050137204-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
| US-20050137184-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBVIE INC. | 2005-06-23 | — | — | US | disclosed |
| US-20050137219-A1 | Spirocyclic quinuclidinic ether derivatives | ABBVIE INC. | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137217-A1 | Spirocyclic quinuclidinic ether derivatives | CHRNA1, CHRNA7, CHRNA2 | CHRM3 14/4885 |
| US-20080064703-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | IDO1, IDO2, HTR3C | CHRM3 604/4885 |
| US-20050137204-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | CHRNA1, CHRNA7, CHRNA2 | CHRM3 16/4885 |
| US-20050137398-A1 | 3-Quinuclidinyl heteroatom bridged biaryl derivatives | CHRNA1, CHRNA2, CHRM2 | CHRM3 6/4885 |
| US-20050137226-A1 | 3-Quinuclidinyl heteroatom bridged biaryl derivatives | CHRNA3, CHRNA1, CHRM3 | CHRM3 3/4885 |
| US-20050137203-A1 | 3-quinuclidinyl amino-substituted biaryl derivatives | CHRNA9, CHRNA7, CHRNA1 | CHRM3 14/4885 |
| US-20050137184-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | CHRNA1, CHRNA7, CHRNA2 | CHRM3 16/4885 |
| US-20050137219-A1 | Spirocyclic quinuclidinic ether derivatives | CHRNA1, CHRNA7, CHRNA2 | CHRM3 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.